Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination MSC and HSC in Decompensated Cirrhosis
NCT04243681Phase 4Completed
- Sponsor
- Asian Institute of Gastroenterology
- Start
- Jul 2019
- Primary completion
- Aug 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label trial of mesenchymal stem cells and hematopoietic stem cells in Liver cirrhosis (LC) (2 arms), sponsored by Asian Institute of Gastroenterology. Primary endpoint: Safety of combination of hematopoetic and mesenchymal stem cell at 6 months. Started Jul 2019; status: completed.
02
Drugs
mesenchymal stem cellshematopoietic stem cells
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT04243681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243681.